07:00 , Sep 17, 2001 |  BioCentury  |  Tools & Techniques

Potato protected vaccines

Oral vaccines have many benefits over parenteral approaches, but the premature proteolysis and degradation of orally administered antigens in the intestine impedes the production of effective therapeutics. Researchers at the Roswell Park Cancer Institute and...
07:00 , Oct 18, 1999 |  BioCentury  |  Finance

Thallia throws in the towel

Thallia Pharmaceuticals S.A. is a new victim of the mid-life crisis hitting European private companies. On the brink of its first product sales, the pharmaceuticals and nutraceuticals company failed to raise the FF50 million ($8.1...
07:00 , Oct 4, 1999 |  BioCentury  |  Finance

No European bull

London & the Continent No European bull OXFORD - While U.S. biotech companies have benefited from a 12-month bull run, the same cannot be said for the European sector. U.K. biotech stocks may have outperformed...
07:00 , Sep 13, 1999 |  BioCentury  |  Strategy

Mind the gap

OXFORD - Axis Genetics plc has become the first victim of the equity gap threatening U.K. bioscience companies. Axis has run out of money, laid off 25 of its 50 employees, and gone into administration,...
07:00 , Jul 12, 1999 |  BC Week In Review  |  Clinical News

Oral hepatitis B vaccine: Began Phase I trial

Axis Genetics plc , Cambridge, U.K.   Product: Oral hepatitis B vaccine   Business: Infectious diseases   Therapeutic category: Immune stimulation, Viral infection   Target: HBV   Description: Edible plant vaccine (EPV) consisting of potatoes...
07:00 , Jun 14, 1999 |  BC Week In Review  |  Company News

Axis Genetics scientific advisory board update

Axis Genetics plc, Cambridge, U.K.   Business: Infectious diseases   Appointed: Charles Arntzen, president and CEO of the Boyce Thompson Institute, as chairman; Ripley Ballou, head of the department of immunology at the Walter Reed...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Company News

Axis Genetics, Roche Vitamins Inc. deal

Roche Vitamins will evaluate Axis' oral Epicoat chimeric virus particle vaccines for use in animal nutrition and health. The agreement includes a fee-bearing option for Roche Vitamins to obtain a license to the vaccines. (Patent,...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Clinical News

Axis Genetics regulatory update

Axis received U.S. Patent No. 5,874,087 covering its Epicoat chimeric virus particle technology that uses modified plant viruses to display multiple copies of an antigen on their surfaces. Axis also received notice of allowance for...
08:00 , Mar 1, 1999 |  BC Week In Review  |  Company News

Axis Genetics management update

Axis Genetics plc, Cambridge, U.K.   Business: Infectious diseases   Hired: Frank Malinoski as VP of clinical affairs for the U.S. division, formerly SVP of clinical and medical affairs at Nabi  ...
08:00 , Nov 16, 1998 |  BC Week In Review  |  Company News

American Ag-Tec International Ltd., Axis Genetics deal

American Ag-Tec will manufacture and supply for Axis potatoes modified to be edible plant vaccines (EPV) for hepatitis B. Axis will use the EPV potatoes in an oral hepatitis B clinical trial scheduled to begin...